Methylprednisolone plus Upadacitinib then increased Upadacitinib for Ulcerative Colitis
This trial aims to develop personalized treatments for people admitted to hospital with ASUC to help them avoid colectomy & ensure their safety. #ASUC #colectomy
- Ulcerative Colitis
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are individuals aged 50 or older being enrolled in this research?
"This clinical trial is open to patients aged 18-75. For those underage and elderly individuals, there are 71 studies available for minors and 353 trials accessible to seniors."
Is it possible to join the clinical experiment that is currently taking place?
"Admittance to this trial necessitates the presence of ulcerative colitis and a participant's age must lie between 18-75. Currently, 162 applicants are being accepted into this clinical experiment."
Has Methylprednisolone been given the stamp of approval by the U.S. Food and Drug Administration?
"After careful evaluation, Methylprednisolone was given a score of 3 due to Phase 4 trial data that showed the drug's approval."
Are there any openings in this research investigation for new participants?
"The information found on clinicaltrials.gov states that this experiment, which was initially published on May 1st 2023 and later edited on the 6th of the same month, is not currently recruiting patients. However, there are 409 other trials actively seeking participants at present."
What effects and outcomes is this clinical investigation attempting to attain?
"This clinical trial is estimated to take approximately 100 days, and its primary goal is measuring the percentage of participants that complete both intervention and follow-up. Secondary objectives include quantifying colectomy events within the post-intervention period, assessing incidence/severity of adverse events such as shingles, acne, cardiovascular issues etc., and determining if patients are in steroid free remission at 90 day mark."